BioCentury | Oct 8, 2019
Emerging Company Profile

Flagship unveils Cygnal, a nervy take on cancer, inflammation

Cygnal Therapeutics Inc. believes overlooked corners of neurobiology could unlock therapeutic strategies in cancer, inflammation and beyond. With $65 million from Flagship Pioneering and other undisclosed investors, the company launched Tuesday to advance two candidates...
BioCentury | Dec 18, 2014
Distillery Therapeutics

Therapeutics: Angiopoietin 2 (ANG2; ANGPT2); placental growth factor (PGF; PlGF); tissue inhibitor of metalloproteinases 3 (TIMP3)

...al. Immunity; published online Nov. 20, 2014doi:10.1016/j.immuni.2014.11.002 CONTACT: Giuseppe Lembo, IRCCS Neuromed, Pozzilli, Italy e-mail: lembo@neuromed.it BC...
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Jan 7, 2013
Clinical News

Z160: Phase IIa started

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Sep 10, 2012
Clinical News

Z160: Phase IIa started

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Sep 3, 2012
Clinical News

Exalgo regulatory update

...8, 2010). Zalicus gained the U.S. rights to Exalgo through its 2009 merger with Neuromed Pharmaceuticals Ltd. Neuromed...
BioCentury | Mar 19, 2012
Clinical News

Z160: Phase I data

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
Items per page:
1 - 10 of 107
BioCentury | Oct 8, 2019
Emerging Company Profile

Flagship unveils Cygnal, a nervy take on cancer, inflammation

Cygnal Therapeutics Inc. believes overlooked corners of neurobiology could unlock therapeutic strategies in cancer, inflammation and beyond. With $65 million from Flagship Pioneering and other undisclosed investors, the company launched Tuesday to advance two candidates...
BioCentury | Dec 18, 2014
Distillery Therapeutics

Therapeutics: Angiopoietin 2 (ANG2; ANGPT2); placental growth factor (PGF; PlGF); tissue inhibitor of metalloproteinases 3 (TIMP3)

...al. Immunity; published online Nov. 20, 2014doi:10.1016/j.immuni.2014.11.002 CONTACT: Giuseppe Lembo, IRCCS Neuromed, Pozzilli, Italy e-mail: lembo@neuromed.it BC...
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Jan 7, 2013
Clinical News

Z160: Phase IIa started

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Sep 10, 2012
Clinical News

Z160: Phase IIa started

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
BioCentury | Sep 3, 2012
Clinical News

Exalgo regulatory update

...8, 2010). Zalicus gained the U.S. rights to Exalgo through its 2009 merger with Neuromed Pharmaceuticals Ltd. Neuromed...
BioCentury | Mar 19, 2012
Clinical News

Z160: Phase I data

...was discontinued in 2007 after the compound did not demonstrate the necessary "ideal pharmaceutical characteristics." Neuromed Pharmaceuticals Ltd....
Items per page:
1 - 10 of 107